🚀
Enjoy a 7-Day Free Trial Thru Apr 30, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Sinovac Biotech Ltd (NAS:SVA)
News
Sinovac Biotech Ltd
NAS
:SVA (China) Â
$ 6.47
0 (0%)
10:08 PM EST
On watch
P/E:
At Loss
P/B:
0.07
Market Cap:
$ 460.25M
Enterprise V:
$ -6.77B
Volume:
-
Avg Vol (2M):
-
Warning! GuruFocus detected 7 Severe warning signs with SVA.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
-
Market Cap $:
460.25M
PE Ratio:
At Loss
Avg Vol (2M):
-
Enterprise Value $:
-6.77B
PB Ratio:
0.07
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocks™
Compare
0
Summary
30-Y Financials
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Sinovac Biotech Ltd (NAS:SVA) Stock News, Headlines & Updates
Sinovac Biotech Ltd Stock News from GuruFocus
Total 56
1
2
Feb 21, 2024
Sinovac Amends Shareholder Rights Plan
Business Wire
•
2:00am
Jan 18, 2024
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer
Business Wire
•
7:00am
Sep 11, 2023
SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
Business Wire
•
5:00am
Sep 05, 2023
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer
Business Wire
•
4:00am
Aug 29, 2023
Sinovac Confirms Receipt of an Unsolicited Partial Tender Offer
Business Wire
•
3:00am
Aug 28, 2023
Sinovac Announces Change of Legal Representative of Sinovac Beijing
Business Wire
•
7:00am
Aug 15, 2023
SINOVAC Reports Unaudited First Half of 2023 Financial Results
Business Wire
•
6:00am
Sep 01, 2022
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Sinovac Biotech Ltd. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers – SVA
Ds***
•
5:00pm
Aug 25, 2022
SINOVAC BIOTECH LTD. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts
PurpleRose
•
12:00pm
Aug 23, 2022
Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Sinovac Biotech Ltd. (SVA) Investors of Class Action Against 1Globe Capital LLC and to Actively Participate
PurpleRose
•
10:00am
Aug 20, 2022
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sinovac Biotech Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers – SVA
PurpleRose
•
11:00am
SVA Class Action Complaint Filed: Johnson Fistel, Globally-Recognized Law Firm Encourages Shareholders to Submit Their Sinovac Biotech Ltd. Losses for Securities Class Action Against 1Globe Capital LLC and Certain of its Officers
PurpleRose
•
8:00pm
Aug 16, 2022
Pomerantz Law Firm Announces the Filing of a Class Action Against 1Globe Capital LLC and Certain Officers, on behalf of Shareholders of Sinovac Biotech Ltd. – SVA
PurpleRose
•
5:00pm
Jul 19, 2021
SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy
Business Wire
•
7:00am
Jul 12, 2021
SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX
Business Wire
•
5:00am
Jun 30, 2021
The Lancet Infectious Diseases Published Data from Sinovac's Phase I/II Study, World's First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years Old
Business Wire
•
6:00am
Jun 02, 2021
World Health Organization Authorizes SINOVAC's CoronaVac® for Emergency Use
Business Wire
•
7:00am
Feb 23, 2021
Sinovac Amends Shareholder Rights Plan
Business Wire
•
7:00pm
Feb 08, 2021
Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine
Business Wire
•
7:00am
Feb 06, 2021
Sinovac Announces Phase III Results of Its COVID-19 Vaccine
Business Wire
•
7:00pm
Feb 03, 2021
Sinovac Files for Conditional Market Authorization of COVID-19 Vaccine in China
Business Wire
•
11:00am
Dec 23, 2020
1Globe Capital, the Largest Shareholder of Sinovac Biotech, Reached Agreement with SEC and Calls on All Stakeholders to Support Sinovac's COVID-19 Vaccine Program
Marketwired
•
7:00am
Dec 09, 2020
Sinovac Announces Product License for 23-Valent Pneumococcal Polysaccharide Vaccine
Business Wire
•
7:00am
Dec 07, 2020
Sinovac Secures Approximately $500 Million in Funding for COVID-19 Vaccine Development
Business Wire
•
7:00pm
Sep 28, 2020
Beijing Fourth Intermediate People's Court Issues Judgement Against Sinobioway Medicine and Mr. Aihua Pan
Business Wire
•
11:00am
Sep 23, 2020
Sinovac's Coronavac™, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children
Business Wire
•
11:00am
Sep 22, 2020
Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey
Business Wire
•
11:00am
Sep 09, 2020
Sinovac Reports Preliminary Phase I/II Results of COVID-19 Vaccine in Elderly Volunteers
Business Wire
•
3:00pm
Aug 25, 2020
Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation
Business Wire
•
11:00am
Jul 06, 2020
Sinovac COVID-19 Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial
Business Wire
•
11:00am
Jun 25, 2020
Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine
Business Wire
•
7:00pm
Jun 13, 2020
Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccine Candidate Against COVID-19
Business Wire
•
3:00pm
Jun 11, 2020
Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III
Business Wire
•
11:00am
May 22, 2020
Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development
Business Wire
•
11:00am
May 18, 2020
Sinovac Comments on SEC Findings Against Jiaqiang "Chiang" Li and 1Globe Capital
Business Wire
•
11:04am
May 06, 2020
Sinovac Announces First Animal Study Results of Vaccine Against COVID-19 Published in SCIENCE
Business Wire
•
11:00am
Apr 17, 2020
Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19
Business Wire
•
11:00am
Apr 15, 2020
Sinovac Announces Approval of Human Clinical Trial for a Vaccine Candidate Against COVID-19
Business Wire
•
7:00pm
Oct 17, 2018
U.S. District Court in Massachusetts Denies 1Globe's Motion for Preliminary Injunction to Enjoin Sinovac's Issuance of Shares
PRNewswire
•
7:04am
Sep 17, 2018
DOJ Closes Investigation of Sinovac
PRNewswire
•
11:33am
Total 56
1
2
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news